Melissa Ching Ching Teo1, Claramae Shulyn Chia1, Cindy Lim2, Grace Hwei Ching Tan1, Whay Kuang Chia3, Khee Chee Soo1. 1. Division of Surgical Oncology, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore. 2. Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore. 3. Division of Medical Oncology, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore.
Abstract
BACKGROUND: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastases from ovarian cancer have been shown to have a role in recurrent ovarian cancer, but are still not considered standard therapy. METHODS: From March 2005 to July 2013, 41 patients who underwent 44 CRS and HIPEC for peritoneal metastases in recurrent ovarian cancer were included in this study. Details were obtained from a prospectively maintained database. Our aim was to report our 5-year overall and disease-free survivals, as well as prognostic factors for survival. RESULTS: Median age was 50 years old (range 23-73). Median duration of surgery was 510 min (range 230-840) and median peritoneal carcinomatosis index (PCI) score was 9.5 (range 0-31). About 92.7% of the patients had completeness of cytoreduction (CC) scores of 0 or 1. Median follow-up was 43.9 months (range 0.7-108.9). There were no mortalities and the high-grade morbidity rate was 31.8%. Median overall survival was 42.8 months (range 28.6-99.9) 5-year overall and disease-free survivals were 49.3% and 7.5% respectively. On multivariate analysis, histology and CC score were significantly associated with overall survival while histology and disease-free interval were associated with disease-free survival. The odds of developing a high-grade complication more than doubled for each additional surgical procedure performed (p=0.01). CONCLUSIONS: CRS and HIPEC can attain prolonged survival in selected patients with peritoneal metastasis in recurrent ovarian cancer.
BACKGROUND: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastases from ovarian cancer have been shown to have a role in recurrent ovarian cancer, but are still not considered standard therapy. METHODS: From March 2005 to July 2013, 41 patients who underwent 44 CRS and HIPEC for peritoneal metastases in recurrent ovarian cancer were included in this study. Details were obtained from a prospectively maintained database. Our aim was to report our 5-year overall and disease-free survivals, as well as prognostic factors for survival. RESULTS: Median age was 50 years old (range 23-73). Median duration of surgery was 510 min (range 230-840) and median peritoneal carcinomatosis index (PCI) score was 9.5 (range 0-31). About 92.7% of the patients had completeness of cytoreduction (CC) scores of 0 or 1. Median follow-up was 43.9 months (range 0.7-108.9). There were no mortalities and the high-grade morbidity rate was 31.8%. Median overall survival was 42.8 months (range 28.6-99.9) 5-year overall and disease-free survivals were 49.3% and 7.5% respectively. On multivariate analysis, histology and CC score were significantly associated with overall survival while histology and disease-free interval were associated with disease-free survival. The odds of developing a high-grade complication more than doubled for each additional surgical procedure performed (p=0.01). CONCLUSIONS: CRS and HIPEC can attain prolonged survival in selected patients with peritoneal metastasis in recurrent ovarian cancer.
Authors: H Bonnefoi; R P A'Hern; C Fisher; V Macfarlane; D Barton; P Blake; J H Shepherd; M E Gore Journal: J Clin Oncol Date: 1999-03 Impact factor: 44.544
Authors: Vic J Verwaal; Serge van Ruth; Eeclo de Bree; Gooike W van Sloothen; Harm van Tinteren; Henk Boot; Frans A N Zoetmulder Journal: J Clin Oncol Date: 2003-10-15 Impact factor: 44.544
Authors: Dennis S Chi; Corinna C Franklin; Douglas A Levine; Faina Akselrod; Paul Sabbatini; William R Jarnagin; Ronald DeMatteo; Elizabeth A Poynor; Nadeem R Abu-Rustum; Richard R Barakat Journal: Gynecol Oncol Date: 2004-09 Impact factor: 5.482
Authors: Dominique Elias; Jean-Robert Delperro; Lucas Sideris; Ellen Benhamou; Marc Pocard; Olivier Baton; Marc Giovannini; Philippe Lasser Journal: Ann Surg Oncol Date: 2004-05 Impact factor: 5.344
Authors: Lukas F Liesenfeld; Benedikt Wagner; H Christian Hillebrecht; Maik Brune; Christoph Eckert; Johannes Klose; Thomas Schmidt; Markus W Büchler; Martin Schneider Journal: Ann Surg Oncol Date: 2021-07-14 Impact factor: 5.344